partneringNEWS

Biotech funding 2012: Innovation is not enough

ctheodoropulos — Mon, 16 Jan 2012 19:36:38 +0000

Venture capital is the most expensive form of capital, so companies are advised to be creative in sourcing other types of funding. With the current capital headwinds, creative alternatives may be the only options companies have. Read more »

Balancing on the innovation high wire

ctheodoropulos — Fri, 13 Jan 2012 18:51:27 +0000

The bar is higher than it has ever been for emerging innovators to secure a partnership. Speakers at Tuesday’s plenary luncheon at Biotech Showcase™ 2012 spoke of the realities and substantial challenges of an environment that increasingly incorporates external and internal development programs. Read more »

Lights are flashing green for biotech investment in China

ctheodoropulos — Fri, 13 Jan 2012 18:51:08 +0000

While the rest of the world struggles, China is setting new records in venture capital investment, IPO and M&A activity, and partnering deals. Read more »

The exciting state of regenerative medicine

ctheodoropulos — Fri, 13 Jan 2012 18:50:36 +0000

Regenerative medicine has the power to transform healthcare, incorporating a wide variety of therapies. When incorporated into clinical practice, regenerative therapies may save USD 250 billion per year in the US alone. Read more »

Biotech investors declare it’s never too early to plan an exit

ctheodoropulos — Fri, 13 Jan 2012 18:49:04 +0000

It’s never too early to plan an exit strategy. Panelists at the Biotech Showcase™ 2012 luncheon plenary session Monday all agreed that, although that strategy may include an IPO, exit planning should include other strategies as well. Read more »

The number two killer globally, infectious disease is a great place to invest

ctheodoropulos — Fri, 13 Jan 2012 18:47:55 +0000

Infectious diseases are the number two killer globally, just behind cardiovascular disease. Aside from the scientific challenges, biotech companies conducting infectious disease work are moving from seemingly random approaches to iterative optimizations that deliver candidates on schedule, cost-effectively, said expert panelists at Biotech Showcase™ 2012. Read more »

No related posts.

Harry Glorikian: Opportunities in this market are abundant, but not obvious

ctheodoropulos — Wed, 04 Jan 2012 18:28:43 +0000

For many years Harry Glorikian, Managing Director, Scientia Advisors has been helping companies navigate the dynamic, yet increasingly turbulent, life science market. Over the holidays we had the chance to meet with Glorikian to get a peek at what’s in store for several sectors in the healthcare industry in 2012 and beyond. Read more »

Seegene: Multiplex assays key to companion diagnostics

ctheodoropulos — Wed, 04 Jan 2012 18:27:10 +0000

The quality of medical treatment is dependent on rapid and accurate diagnosing of the disease, as well as safeguarding the life of the patient. Apart from infectious diseases, most diseases do not have that "tell-all" diagnostic marker that provides an adequate picture of the patient and their particular disease. Seegene, Inc., sees a combination of surrogate markers in a single clinically validated assay as the most effective tool in disease identification, treatment and management, while keeping the patient in focus. Read more »

Pricing and reimbursement: Knowing your value up front is key to future dealmaking

Anton Gueth: Troublesome financing environment to hit early stage companies hard in 2012

ctheodoropulos — Wed, 04 Jan 2012 18:25:30 +0000

The excitement of the industry insiders is unfortunately not matched by those funding and regulating it. The challenges facing the industry are increasing every day. Read more »

Video: Recognizing and avoiding mistakes that can cost you the deal

kmuller — Wed, 04 Jan 2012 18:18:47 +0000

Valuable lessons are learned when experienced business development executives draw from their dealmaking experience and dive into some of the common and not so common pitfalls in partnering. Read more »

partneringNEWS

Biotech funding 2012: Innovation is not enough

Related Posts

Balancing on the innovation high wire

Related Posts

Lights are flashing green for biotech investment in China

Related Posts

The exciting state of regenerative medicine

Related Posts

Biotech investors declare it’s never too early to plan an exit

Related Posts

The number two killer globally, infectious disease is a great place to invest

Related Posts

Harry Glorikian: Opportunities in this market are abundant, but not obvious

Related Posts

Seegene: Multiplex assays key to companion diagnostics

Related Posts

Anton Gueth: Troublesome financing environment to hit early stage companies hard in 2012

Related Posts

Video: Recognizing and avoiding mistakes that can cost you the deal

Related Posts